Vermont Immunobiology / Infectious Diseases Center

佛蒙特州免疫和传染病中心(VCIID)Cobre即将进入第10个年头。在此期间，VCIID从9名创始教员发展到25名，出版了416份出版物，获得了9200万美元的赠款支持和14项专利。在第一和第二阶段，12名初级教员获得了科布雷资助(10名终身教员，5名已经获得终身教职)，他们发表了118篇论文，获得了1320万美元的资助(包括4名新的R01助学金)，当时他们还是初级教员。初级教师还获得了几个奖项，包括皮尤学者奖。在此期间，佛蒙特州大学(UVM)提供的机构支助也高达290万美元。VCIID已经通过各种指标证明了它已发展成为一个成熟的协作中心。它的教职员工已经获得了P01项目资助和T32培训资助，这两项资助都得到了续签。其中一所前初级学院成立了疫苗检测中心(VTC)，作为VCIID的临床试验部门。它目前正在用NIAID的资金进行一种新的登革热病毒疫苗的试验，并研究为什么在比尔和梅林达·盖茨基金会的资助下，孟加拉国营养不良的儿童对脊髓灰质炎病毒没有反应。到目前为止，职训局已收到1,850万元的拨款。为了满足VCIID教职员工对BSL3设施日益增长的需求， 我们通过利用Cobre ARRA补充资金来支持与佛蒙特州卫生部的合作项目，在该项目中，UVM捐赠了UVM园区的土地，建造了一个新的卫生部实验室，其中包含一个由卫生部支付和维护的大型BSL3/ABSL3联合设施，这在经济上是创新的。这也将促进VCIID调查人员和卫生部工作人员之间的互动，从而将我们带入公共卫生领域。随着我们接近第三阶段，我们将通过一个试点项目计划来激励VCIID教职员工在共同的研究主题上进行合作，为新的协作R01、P01和U-19应用做准备，并通过我们新的SPARK-VT计划将他们的研究朝着翻译和创业的方向发展。我们在基因组技术/生物信息学和质谱学/蛋白质组学方面的核心都在第二阶段升级了仪器，并使其用户基础多样化。结合第三阶段结束后五年的机构承诺，我们认为我们已经达到了开始一个成功的第三阶段科布雷时期的指标。

The Vermont Center for Immunology and Infectious Diseases (VCIID) COBRE is about to enter its 10th year. During this period, VCIID has grown from 9 founding faculty to 25 and produced 416 publications and $92 million in grant support and 14 patents. Twelve junior faculty were supported with COBRE funding during Phases I and II (10 tenure track and 5 have already achieved tenure) and they published 118 papers and garnered $13.2 million in funding (including 4 new R01 grants) while still junior faculty. Junior faculty also received several awards, including a Pew Scholars Award. Institutional support from the University of Vermont (UVM) during this period was also a robust $2.9 million. The VCIID has demonstrated its development into a mature collaborative center by a variety of metrics. Its faculty has received a P01 Program Project Grant and a T32 Training Grant, both of which were renewed. One of the former junior faculties has established the Vaccine Testing Center (VTC) as a clinical trials wing of the VCIID. It is currently conducting trials for a new dengue virus vaccine with NIAID funding, and examining why undernourished children in Bangladesh do not respond to polio virus with funding from the Bill & Melinda Gates Foundation. To date VTC has received $18.5 million in funding. To fulfill a growing need for a BSL3 facility for VCIID faculty, we were economically innovative by leveraging a COBRE ARRA supplement to support a collaborative venture with the Vermont Department of Health in which UVM donated land on the UVM campus to build a new Department of Health laboratory containing a large joint BSL3/ABSL3 facility paid and maintained by the Department of Health. This will also foster interactions between VCIID investigators and Department of Health staff, and hence move us into the realm of public health. As we approach Phase III we will motivate VCIID faculty through a Pilot project Program to collaborate on common research themes to prepare for new collaborative R01, P01 and U-19 applications, as well as to move their research in a translational and entrepreneurial direction with our new SPARK-VT Program. Our cores in Genome Technologies/Bioinformatics and Mass Spectrometry/Proteomics have both upgraded instrumentation during Phase II and diversified their user base. Combined with institutional commitments for five years beyond the end of Phase III, we feel we have achieved the metrics to begin a successful Phase III COBRE period.